Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer

Abstract Lung cancer remains the leading cause of cancer death throughout the world. Despite new chemotherapeutic, immunomodulating and molecularly targeted agents, patients with locally advanced or metastatic disease still have a poor prognosis. This trial looked to combine antiangiogenic therapy w...

Full description

Bibliographic Details

Published in:	Cancer Medicine
Main Authors:	Nicole F. Laslett, SuJung Park, Gregory A. Masters, David D. Biggs, Charles J. Schneider, Jamal G. Misleh, Kathir Suppiah, Pamela S. Simpson, Stephen Grubbs, Timothy F. Wozniak, Michael Guarino
Format:	Article
Language:	English
Published:	Wiley 2018-07-01
Subjects:	bevacizumab carboplatin molecular therapy nonsquamous non–small‐cell lung cancer pemetrexed
Online Access:	https://doi.org/10.1002/cam4.1569